国内干眼药物治疗领域正在加速变革。 干眼新机制药物初露头角 长期以来，传统干眼药物多聚焦于缓解症状，以玻璃酸钠滴眼液为代表的人工泪液是主流产品。在医药电商平台的干眼用药销售排行榜上，前十位产品绝 大多数为玻璃酸钠滴眼液。 在国内眼科市场，一批已上市干眼新药开始崭露头角，填补传统治疗的空白。 这些新机制药物凭借从源头解决干眼问题的临床价值，已初步获得市场认可，一组销售数据可以佐证。 2025年，恒瑞医药用于干眼的"恒沁"全氟己基辛烷滴眼液上市，电商平台零售价468元/盒，在京东大药房上线3个多月（1盒装）销量达到5000+，并跻 身"眼干涩"用药排行榜第8。2024年底，远大医药引进的酒石酸伐尼克兰鼻喷雾剂在国内获批上市，零售价599元/支，2025年上半年成为远大医药五官科 收入增长的动力之一。 与传统干眼药物相比，这些基于新机制的干眼药物价格高出几倍甚至十倍，仍实现了上市即热销。这是否意味着，干眼药物市场的竞争逻辑与发展格局或 将发生变革？ 睑板腺功能障碍（MGD）是睑板腺的慢性、非特异性炎症，以睑板腺导管的阻塞或睑板腺分泌物异常为特征，是蒸发过强型干眼的主要原因。有临床研 究显示，69%—86%的干眼人群 ...

Core Insights - The increasing prevalence of dry eye patients in China highlights a gap in public understanding, which remains focused on temporary relief through eye drops rather than addressing underlying issues [2] - The launch of the innovative drug, the tobramycin nasal spray, represents a shift towards a "repair-type" strategy for treating dry eye, aiming to restore tear gland function and enhance natural tear production [2][4] - The conference held on October 25 showcased the new nasal spray and brought together leading experts to discuss advancements in dry eye treatment and the establishment of a healthy ocular ecosystem [4] Group 1: Medical Insights - Experts from Xiamen University and Huazhong University of Science and Technology discussed typical symptoms and high-risk groups for dry eye, emphasizing the need for new treatment methods that actively stimulate tear production [1] - Clinical evidence presented by Zhejiang University highlighted the long-term benefits of the nasal spray in promoting secretion and providing rapid anti-inflammatory effects [1] - The transition from "supplementing water" to "producing water" in dry eye treatment was analyzed, focusing on the innovative mechanism of the nasal spray that activates tear secretion through neural stimulation [1] Group 2: Industry Developments - The traditional approach of using artificial tears is criticized for its limitations, including dependency and potential suppression of natural tear production, which can worsen the condition over time [2] - The launch of the nasal spray aligns with the strategic vision of the company to enhance its portfolio in ophthalmology, with plans for multiple new drug approvals in the next three years targeting various eye conditions [2]